| Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone … F Gay, P Musto, D Rota-Scalabrini, L Bertamini, A Belotti, M Galli, ... The Lancet Oncology 22 (12), 1705-1720, 2021 | 180 | 2021 |
| Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomized forte trial F Gay, P Musto, DR Scalabrini, M Galli, A Belotti, E Zamagni, L Bertamini, ... Blood 136, 35-37, 2020 | 70 | 2020 |
| Whole-genome sequencing analysis of semi-supercentenarians P Garagnani, J Marquis, M Delledonne, C Pirazzini, E Marasco, ... Elife 10, e57849, 2021 | 53 | 2021 |
| High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma L Bertamini, S Oliva, D Rota-Scalabrini, L Paris, S Morè, P Corradini, ... Journal of Clinical Oncology 40 (27), 3120-3131, 2022 | 39 | 2022 |
| MRD assessment in multiple myeloma: progress and challenges L Bertamini, M D’Agostino, F Gay Current hematologic malignancy reports 16 (2), 162-171, 2021 | 37 | 2021 |
| Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned … R Mina, P Musto, D Rota-Scalabrini, L Paris, B Gamberi, A Palmas, ... The Lancet Oncology 24 (1), 64-76, 2023 | 35 | 2023 |
| Pursuing a curative approach in multiple myeloma: a review of new therapeutic strategies M D’Agostino, L Bertamini, S Oliva, M Boccadoro, F Gay Cancers 11 (12), 2015, 2019 | 32 | 2019 |
| Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in … F Gay, R Mina, D Rota-Scalabrini, M Galli, A Belotti, E Zamagni, ... Journal of Clinical Oncology 39 (15_suppl), 8002-8002, 2021 | 23 | 2021 |
| Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia L Bertamini, J Nanni, G Marconi, M Abbenante, V Robustelli, F Bacci, ... BMC cancer 18, 1-5, 2018 | 18 | 2018 |
| Beyond clinical trials in patients with multiple myeloma: a critical review of real-world results L Bertamini, G Bertuglia, S Oliva Frontiers in Oncology 12, 844779, 2022 | 14 | 2022 |
| Poor prognosis of multiple myeloma predicted by high levels of circulating plasma cells is independent from other high-risk features but is modulated by the achievement of … L Bertamini, M Grasso, M D'Agostino, A Pascarella, P Tosi, F Monaco, ... Blood, The Journal of the American Society of Hematology 136 (Supplement 1 …, 2020 | 13 | 2020 |
| Development and validation of a simplified score to predict early relapse in newly diagnosed multiple myeloma in a pooled dataset of 2,190 patients GM Zaccaria, L Bertamini, MT Petrucci, M Offidani, P Corradini, A Capra, ... Clinical Cancer Research 27 (13), 3695-3703, 2021 | 10 | 2021 |
| When and how to treat relapsed multiple myeloma N Nathwani, L Bertamini, R Banerjee, F Gay, N Shah, A Krishnan American Society of Clinical Oncology Educational Book 41, 358-375, 2021 | 7 | 2021 |
| MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia G Marconi, A Talami, MC Abbenante, C Sartor, S Parisi, J Nanni, ... European Journal of Haematology 105 (1), 47-55, 2020 | 6 | 2020 |
| Integrative analysis of baseline prognostic features and achievement of minimal residual disease negativity as predictors of early relapse in transplant-eligible multiple … F Gay, GM Zaccaria, M Offidani, F Vozella, P Becco, A Belotti, A Capra, ... Blood 134, 605, 2019 | 5 | 2019 |
| Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study … E Zamagni, S Oliva, F Gay, A Capra, D Rota-Scalabrini, M D'Agostino, ... EClinicalMedicine 60, 2023 | 4 | 2023 |
| Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients G Marconi, S De Polo, G Martinelli, J Nanni, L Bertamini, A Talami, M Olivi, ... Leukemia Research 101, 106497, 2021 | 4 | 2021 |
| New drugs in early development for treating multiple myeloma: all that glitters is not gold L Bertamini, F Bonello, M Boccadoro, S Bringhen Expert Opinion on Investigational Drugs 29 (9), 989-1004, 2020 | 4 | 2020 |
| Moving toward continuous therapy in multiple myeloma F Bonello, G Cetani, L Bertamini, F Gay, A Larocca Clinical Hematology International 1 (4), 189-200, 2019 | 4 | 2019 |
| Checkpoint inhibitors and myeloma: Promises, deadlocks and new directions L Bertamini, F Gay Annals of Translational Medicine 8 (12), 2020 | 3 | 2020 |
